A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-74
SponsorSinglera Genomics Inc.

About this trial

This is a cross-sectional cohort study based on community population jointly developed by Northern Jiangsu People's Hospital and Shanghai Kunyuan Biological Technology Co., LTD. This study will verify the real world results of polygene methylation detection of colorectal cancer in a large prospective cohort of community population, which is expected to enroll 80,000 permanent residents in Yangzhou city. The preliminary design period of the study is 5 years. In this study, questionnaire survey and polygene methylation test of colorectal cancer were used as the primary screening method, and colonoscopy was used as the further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination. The evaluation indexes include sensitivity, specificity, detection rate of precancerous lesions and adenoma.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

1) Permanent resident population of Yangzhou; 2) Chronological age: 40~74 years, including critical value (refer to birth date of id card); 3) Have full capacity of conduct; 4) After enrollment, they could voluntarily cooperate to complete the Colorectal cancer Risk Factor Assessment Questionnaire and accept telephone follow-up; 5) Agree to timely feed back the information related to tumor diagnosis to the investigator during the study process; 6) Willing and able to sign informed consent.

Disqualifiers

1) History of colorectal cancer and other malignant tumors; 2) previous colorectal resection; 3) are receiving any cancer-related treatment; 4) Those who have received major surgical treatment such as blood transfusion and transplantation within 3 months; 5) Participate in other interventional clinical investigators within 3 months; 6) Pregnant or lactating women; 7) Patients with autoimmune diseases, genetic diseases, mental diseases/disabilities and other diseases considered unsuitable for the study by the researcher; 8) Poor compliance, unable to complete the study according to the judgment of the researcher.

Trial population

The subjects of this study were permanent residents in Yangzhou who met the inclusion criteria

Trial design

Design model

Ecologic or community

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

80,000 Participants
are grouped into 1 trial group
Group A: Positive group

Trial outcomes

Primary outcomes

1

Evaluation of polygenic methylation detection in colorectal cancer

To evaluate the sensitivity, specificity, and positive/negative predictive value of polygenic methylation tests for colorectal cancer in subjects

Time frame
assessed up to 5 years
2

Application value of polygene methylation detection in colorectal cancer in community population

To verify the effectiveness and clinical value of this detection method in the diagnosis of colorectal cancer in yangzhou community population.

Time frame
assessed up to 5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Singlera Genomics Inc.

Lead sponsor

Northern Jiangsu People's Hospital

Collaborator